Special Issue "Diagnosis and Treatment of Upper Gastrointestinal Malignancies: Current Advances and Future Prospects"

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 30 November 2022 | Viewed by 1125

Special Issue Editor

Dr. Jun Gong
E-Mail Website
Guest Editor
Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Interests: gastroesophageal cancer; colorectal cancer; hepatobiliary cancer; pancreatic cancer; targeted therapies; immunotherapy; developmental therapeutics; biomarker design

Special Issue Information

Dear Colleagues,

Cancers of the upper gastrointestinal tract constitute a high global burden, with gastric and esophageal cancers representing the fifth and sixth most common cancers worldwide, respectively. Cancers of the esophagus, stomach, and small bowel comprise a heteregenous group of malignancies distinguished by differences in histopathologic classification, risk factors and etiologies, and incidence and epidemiologic patterns, and, more recently, with comprehensive molecular profiling and molecular classification, leading to precision-based systemic therapy options in select scenarios. Despite improvements in screening, diagnosis, and radiation, surgical, and systemic therapies, global survival rates remain unsatisfactory, and the disease remains incurable in advanced stages.

The focus of this Special Issue is to highlight our global research efforts to improve outcomes in patients with upper gastrointestinal cancers. We recognize that dramatic improvements in the management of these malignancies in recent decades have resulted from multidisciplinary evaluation and treatment of patients. As such, we invite colleagues from across all disciplines: epidemiology, basic and translational science, genetics, nutrition, surgery, surgical oncology, hematology and oncology, radiation oncology, radiology, interventional radiology, gastroenterology, interventional gastroenterology, palliative care, and pathology, to highlight recent advancements in their respective fields that have contributed to the global care of patients with upper gastrointestinal cancers.

Dr. Jun Gong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • esophageal cancer
  • small bowel cancer
  • gastrointestinal cancer
  • screening
  • diagnosis
  • surgery
  • endoscopic
  • systemic therapy
  • radiation therapy

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Jump to: Other

Review
Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
Diseases 2022, 10(2), 23; https://doi.org/10.3390/diseases10020023 - 19 Apr 2022
Viewed by 460
Abstract
Gastroesophageal cancer is one of the most common cancers in the world, with a high rate of mortality. While there has been significant progress over the past decade, particularly with the addition of anti-HER2 therapies to platinum-based chemotherapy agents in the advanced setting, [...] Read more.
Gastroesophageal cancer is one of the most common cancers in the world, with a high rate of mortality. While there has been significant progress over the past decade, particularly with the addition of anti-HER2 therapies to platinum-based chemotherapy agents in the advanced setting, the prognosis remains poor and the treatment options for this disease entity remain limited. In this review, we discuss the current therapeutic landscape for HER2-positive gastroesphageal cancer and the seminal clinical trials that have shaped our approach to this disease entity. In addition, we highlight some of the challenges to the understanding and management of this disease, specifically discussing the breadth of molecular diversity and intratumoral heterogeneity of HER2 expression that impact the clinical efficacy and prognosis. Furthermore, we discuss the potential role of next-generation sequencing (NGS) and circulating-tumor DNA (ctDNA) as complementary tools to immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH) to guiding clinical decision making. Finally, we highlight promising clinical trials of new treatment regimens that will likely reshape the therapeutic approach to this disease entity. Full article

Other

Jump to: Review

Brief Report
Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma—A Case Series of Non-Operative Long-Term Survivors
Diseases 2022, 10(2), 24; https://doi.org/10.3390/diseases10020024 - 24 Apr 2022
Viewed by 406
Abstract
Checkpoint inhibitor (CPI) therapy has only recently been introduced in the first-line treatment of advanced gastric cancer. However, later line monotherapy CPI efficacy in a subset of patients was presented about four years prior. Here, we present three cases of advanced gastric adenocarcinoma [...] Read more.
Checkpoint inhibitor (CPI) therapy has only recently been introduced in the first-line treatment of advanced gastric cancer. However, later line monotherapy CPI efficacy in a subset of patients was presented about four years prior. Here, we present three cases of advanced gastric adenocarcinoma cancers treated with CPI in early lines years prior to the availability of randomized first line data. All three patients remain in remission without gastrectomy, with the median time from initial diagnosis of approximately 52 months. With long-term follow-up of more than four years, we present a proof of concept that, with early integration of CPI therapy, highly durable responses are possible even in the absence of surgery in patients with advanced gastric and gastroesophageal junction cancers. Full article
Show Figures

Figure 1

Back to TopTop